Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Market Cap	86.27M
Revenue (ttm)	n/a
Net Income (ttm)	-39.26M
Shares Out	27.92M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,535
Open	3.050
Previous Close	3.020
Day's Range	2.950 - 3.150
52-Week Range	2.670 - 9.250
Beta	-0.02
Analysts	Strong Buy
Price Target	16.75 (+442.07%)
Earnings Date	Apr 15, 2024

About RVPH

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, atte...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: RVPH

Analyst Forecast

According to 4 analysts, the average rating for RVPH stock is "Strong Buy." The 12-month stock price forecast is $16.75, which is an increase of 442.07% from the latest price.

Price Target

$16.75

(442.07% upside)

Analyst Consensus: Strong Buy